search for


Subfoveal Choroidal Thickness Changes after Intravitreal Bevacizumab in Macular Edema Secondary to Retinal Vein Occlusion
망막정맥폐쇄로 인한 황반부종에서 유리체내 베바시주맙주입술 후 황반하 맥락막 두께의 변화
JKOS 2019 Aug;60(8):740-7
Published online August 15, 2019;
Copyright © 2019 The Korean Ophthalmological Society.
PDF Download Count: 154 / View Count: 136

Jin Young Lee, MD1, Su Jeong Song, MD, PhD1, Mi Yeon Lee, MPH2, Jeong Hun Bae, MD, PhD1
이진영1 · 송수정1 · 이미연2 · 배정훈1

Department of Ophthalmology, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine1, Seoul, Korea
Department of Biostatistics, Kangbuk Samsung Hospital2, Seoul, Korea
성균관대학교 의과대학 강북삼성병원 안과학교실1, 강북삼성병원 연구지원팀2
Received September 13, 2018; Revised December 7, 2018; Accepted July 18, 2019.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Purpose: To determine changes in subfoveal choroidal thickness (SCT) after intravitreal injection of bevacizumab in eyes with macular edema secondary to retinal vein occlusion (RVO).
Methods: Forty-four patients treated with intravitreal bevacizumab for unilateral macular edema due to RVO were retrospectively reviewed. Before injection, patients underwent best-corrected visual acuity (BCVA) assessment, dilated fundus examination, fluorescein angiography, and enhanced depth imaging optical coherence tomography. Changes in BCVA, SCT, and central macular thickness (CMT) of the RVO eyes were evaluated and compared with those of the normal contralateral eyes at baseline and at 1, 3, and 6 months after injection.
Results: The mean SCT in RVO eyes (265.41 ± 43.02 µm) was significantly thicker than that in the fellow eyes (244.77 ± 30.35 µm) at baseline (p < 0.001). The mean SCT was significantly reduced at 1, 3, and 6 months after intravitreal bevacizumab injection (all p < 0.001), and the change in SCT was significantly correlated with the change in CMT (r = 0.327, p = 0.030). While there was an improvement in BCVA together with a reduction in SCT (p < 0.001), no significant correlation was found (p = 0.126).
Conclusions: Subfoveal choroidal thickness in RVO eyes with macular edema was greater than that in the normal fellow eyes, and decreased significantly after intravitreal bevacizumab injection. The SCT reduction was significantly correlated with CMT reduction.
Keywords : Bevacizumab, Central macular thickness, Retinal vein occlusion, Subfoveal choroidal thickness


December 2019, 60 (12)